Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency.
10.3346/jkms.2010.25.10.1427
- Author:
Pyoeng Gyun CHOE
1
;
Wan Beom PARK
;
Jin Su SONG
;
Nak Hyun KIM
;
Kyoung Ho SONG
;
Sang Won PARK
;
Hong Bin KIM
;
Nam Joong KIM
;
Myoung Don OH
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. mdohmd@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
HIV;
Acquired Immunodeficiency Syndrome;
Atazanavir;
Hyperbilirubinemia;
Jaundice
- MeSH:
Adult;
Alleles;
Anti-HIV Agents/*adverse effects/therapeutic use;
Asian Continental Ancestry Group/*genetics;
Female;
Follow-Up Studies;
Gene Frequency;
Glucuronosyltransferase/blood/*genetics;
HIV Infections/complications/*drug therapy;
Humans;
Hyperbilirubinemia/complications/*epidemiology/genetics;
Incidence;
Male;
Middle Aged;
Oligopeptides/*adverse effects/therapeutic use;
Promoter Regions, Genetic;
Pyridines/*adverse effects/therapeutic use;
Republic of Korea
- From:Journal of Korean Medical Science
2010;25(10):1427-1430
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hyperbilirubinemia is frequently observed in Caucasian HIV patients treated with atazanavir. UDP-glucuronosyltransferase 1A1 polymorphism, UGT1A1*28, which is associated with atazanavir-induced hyperbilirubinemia, is less common in Asians than in Caucasians. However, little is known about the incidence of atazanavir-associated hyperbilirubinemia in Asian populations. Our objective was to investigate the incidence of and tolerability of atazanavir-associated hyperbilirubinemia in Korean HIV patients. The prevalence and cumulative incidence of atazanavir-associated hyperbilirubinemia and UGT1A1*28 allele frequency was investigated in 190 Korean HIV-infected patients treated with atazanavir 400 mg per day. The UGT1A1*28 were examined by direct sequencing of DNA from peripheral whole blood. The UGT1A1*28 allele frequency was 11%. The cumulative incidence of any grade of hyperbilirubinemia was 77%, 89%, 98%, and 100%, at 3, 12, 24, and 30 months, respectively. The cumulative incidence of severe (grade 3-4) hyperbilirubinemia was 21%, 41%, 66%, and 75%, at 3, 12, 24, and 30 months, respectively. However, the point prevalence of severe hyperbilirubinemia did not increase with time and remained around 25%. Our data suggest that atazanavir-associated hyperbilirubinemia is common but transient in a population with low UGT1A1*28 allele frequency.
